FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3089405003> ?p ?o ?g. }

• W3089405003 endingPage "e687" @default.
• W3089405003 startingPage "e677" @default.
• W3089405003 abstract "Background Updated WHO guidelines recommend a dolutegravir-based regimen as the preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. We aimed to report the non-inferior efficacy of dolutegravir compared with efavirenz 400 mg at week 96. Methods We did a multicentre, randomised, open label, phase 3 trial in in three hospitals in Yaoundé, Cameroon, in HIV-1 infected antiretroviral-naive adults with an HIV RNA viral load of greater than 1000 copies per mL to compare dolutegravir 50 mg with efavirenz 400 mg (reference treatment), both combined with lamivudine and tenofovir disoproxil fumarate. The primary endpoint was the proportion with a viral load of less than 50 copies per mL at week 48 (10% non-inferiority margin). The study is registered with ClinicalTrials.gov, NCT02777229 and is ongoing. Findings Between July, 2016, and August, 2019, of 820 patients assessed, 613 were randomly assigned to receive at least one dose of study medication, with 310 in the dolutegravir group and 303 in the efavirenz 400 mg group. At week 96 in the intention-to-treat analysis, 229 (74%) of 310 patients receiving dolutegravir and 219 (72%) of 303 patients receiving efavirenz, achieved plasma HIV-1 RNA less than 50 copies per mL (difference 1·6%, 95% CI −5·4 to 8·6; p=0.66). Viral load suppression was reached significantly more rapidly in the dolutegravir group (p<0·001). Virological failure (>1000 copies per mL) was observed in 27 patients (eight in the dolutegravir group, among which, three women switched to efavirenz 600 mg because of the dolutegravir teratogeneicity signal, and 19 in the efavirenz 400 mg group). No acquired resistance mutations to dolutegravir were observed against 17 mutations to efavirenz with or without mutations to lamivudine and tenofovir disoproxil fumarate among the 19 efavirenz 400 mg participants with virological failure. Weight gain was greater in the dolutegravir group (median weight gain, 5·0 kg in the dolutegravir group and 3·0 kg in the efavirenz 400 mg group, p<0·001, and incidence of obesity, 22% in the dolutegravir group and 16% in the efavirenz 400 mg group, p=0·043). The incidence of new WHO HIV-related stage 3 and 4 events was similar in each group (12 [4%] in each group). The two groups had similar rates of serious adverse events (28 [9%] of 310 in the dolutegravir group and 21 [7%] of 303 in the efavirenz 400 mg group). 18 deaths were observed during the 96-week follow-up (eight in the dolutegravir group and ten in the efavirenz 400 mg group). Interpretation The non-inferior efficacy of the dolutegravir-based regimen and non-emergence of dolutegravir resistance at 96 weeks supports its use as a first-line regimen for antiretroviral-naive adults with HIV-1 infection. Viral load suppression was reached more quickly in the dolutegravir group and weight gain was significantly higher. Funding UNITAID and the French National Agency for AIDS Research. Updated WHO guidelines recommend a dolutegravir-based regimen as the preferred first-line treatment for HIV infection and low-dose efavirenz (400 mg) as an alternative. We aimed to report the non-inferior efficacy of dolutegravir compared with efavirenz 400 mg at week 96. We did a multicentre, randomised, open label, phase 3 trial in in three hospitals in Yaoundé, Cameroon, in HIV-1 infected antiretroviral-naive adults with an HIV RNA viral load of greater than 1000 copies per mL to compare dolutegravir 50 mg with efavirenz 400 mg (reference treatment), both combined with lamivudine and tenofovir disoproxil fumarate. The primary endpoint was the proportion with a viral load of less than 50 copies per mL at week 48 (10% non-inferiority margin). The study is registered with ClinicalTrials.gov, NCT02777229 and is ongoing. Between July, 2016, and August, 2019, of 820 patients assessed, 613 were randomly assigned to receive at least one dose of study medication, with 310 in the dolutegravir group and 303 in the efavirenz 400 mg group. At week 96 in the intention-to-treat analysis, 229 (74%) of 310 patients receiving dolutegravir and 219 (72%) of 303 patients receiving efavirenz, achieved plasma HIV-1 RNA less than 50 copies per mL (difference 1·6%, 95% CI −5·4 to 8·6; p=0.66). Viral load suppression was reached significantly more rapidly in the dolutegravir group (p<0·001). Virological failure (>1000 copies per mL) was observed in 27 patients (eight in the dolutegravir group, among which, three women switched to efavirenz 600 mg because of the dolutegravir teratogeneicity signal, and 19 in the efavirenz 400 mg group). No acquired resistance mutations to dolutegravir were observed against 17 mutations to efavirenz with or without mutations to lamivudine and tenofovir disoproxil fumarate among the 19 efavirenz 400 mg participants with virological failure. Weight gain was greater in the dolutegravir group (median weight gain, 5·0 kg in the dolutegravir group and 3·0 kg in the efavirenz 400 mg group, p<0·001, and incidence of obesity, 22% in the dolutegravir group and 16% in the efavirenz 400 mg group, p=0·043). The incidence of new WHO HIV-related stage 3 and 4 events was similar in each group (12 [4%] in each group). The two groups had similar rates of serious adverse events (28 [9%] of 310 in the dolutegravir group and 21 [7%] of 303 in the efavirenz 400 mg group). 18 deaths were observed during the 96-week follow-up (eight in the dolutegravir group and ten in the efavirenz 400 mg group). The non-inferior efficacy of the dolutegravir-based regimen and non-emergence of dolutegravir resistance at 96 weeks supports its use as a first-line regimen for antiretroviral-naive adults with HIV-1 infection. Viral load suppression was reached more quickly in the dolutegravir group and weight gain was significantly higher." @default.
• W3089405003 created "2020-10-08" @default.
• W3089405003 creator A5000476223 @default.
• W3089405003 creator A5004030718 @default.
• W3089405003 creator A5005072339 @default.
• W3089405003 creator A5007529663 @default.
• W3089405003 creator A5012064746 @default.
• W3089405003 creator A5013575025 @default.
• W3089405003 creator A5013916181 @default.
• W3089405003 creator A5016342803 @default.
• W3089405003 creator A5017783904 @default.
• W3089405003 creator A5022215234 @default.
• W3089405003 creator A5023595647 @default.
• W3089405003 creator A5024763793 @default.
• W3089405003 creator A5025746681 @default.
• W3089405003 creator A5025746955 @default.
• W3089405003 creator A5025754562 @default.
• W3089405003 creator A5027279814 @default.
• W3089405003 creator A5027855547 @default.
• W3089405003 creator A5029221966 @default.
• W3089405003 creator A5029233916 @default.
• W3089405003 creator A5031970294 @default.
• W3089405003 creator A5033535702 @default.
• W3089405003 creator A5033880021 @default.
• W3089405003 creator A5038465211 @default.
• W3089405003 creator A5039435667 @default.
• W3089405003 creator A5041053362 @default.
• W3089405003 creator A5041753583 @default.
• W3089405003 creator A5041999431 @default.
• W3089405003 creator A5043125361 @default.
• W3089405003 creator A5044601286 @default.
• W3089405003 creator A5045363590 @default.
• W3089405003 creator A5047298204 @default.
• W3089405003 creator A5047839783 @default.
• W3089405003 creator A5048518493 @default.
• W3089405003 creator A5051817561 @default.
• W3089405003 creator A5051978419 @default.
• W3089405003 creator A5054142063 @default.
• W3089405003 creator A5055130839 @default.
• W3089405003 creator A5057065431 @default.
• W3089405003 creator A5058617930 @default.
• W3089405003 creator A5059371192 @default.
• W3089405003 creator A5059400349 @default.
• W3089405003 creator A5059752923 @default.
• W3089405003 creator A5061527531 @default.
• W3089405003 creator A5063440037 @default.
• W3089405003 creator A5065569613 @default.
• W3089405003 creator A5067148445 @default.
• W3089405003 creator A5068037051 @default.
• W3089405003 creator A5068293589 @default.
• W3089405003 creator A5068809984 @default.
• W3089405003 creator A5068889281 @default.
• W3089405003 creator A5072123589 @default.
• W3089405003 creator A5072567414 @default.
• W3089405003 creator A5074518938 @default.
• W3089405003 creator A5077702074 @default.
• W3089405003 creator A5077968779 @default.
• W3089405003 creator A5079542225 @default.
• W3089405003 creator A5080065932 @default.
• W3089405003 creator A5081979974 @default.
• W3089405003 creator A5082455229 @default.
• W3089405003 creator A5082483900 @default.
• W3089405003 creator A5084776548 @default.
• W3089405003 creator A5087573541 @default.
• W3089405003 creator A5087644865 @default.
• W3089405003 creator A5089692653 @default.
• W3089405003 creator A5090295285 @default.
• W3089405003 date "2020-10-01" @default.
• W3089405003 modified "2023-10-17" @default.
• W3089405003 title "Dolutegravir-based and low-dose efavirenz-based regimen for the initial treatment of HIV-1 infection (NAMSAL): week 96 results from a two-group, multicentre, randomised, open label, phase 3 non-inferiority trial in Cameroon" @default.
• W3089405003 cites W1910280141 @default.
• W3089405003 cites W1990069515 @default.
• W3089405003 cites W2048514971 @default.
• W3089405003 cites W2076175848 @default.
• W3089405003 cites W2094241860 @default.
• W3089405003 cites W2145467751 @default.
• W3089405003 cites W2151050670 @default.
• W3089405003 cites W2184719281 @default.
• W3089405003 cites W2773554166 @default.
• W3089405003 cites W2794281539 @default.
• W3089405003 cites W2886383600 @default.
• W3089405003 cites W2902025352 @default.
• W3089405003 cites W2944376193 @default.
• W3089405003 cites W2947571847 @default.
• W3089405003 cites W2963164305 @default.
• W3089405003 cites W2972599647 @default.
• W3089405003 cites W2995015948 @default.
• W3089405003 cites W3000369307 @default.
• W3089405003 cites W3014615965 @default.
• W3089405003 cites W3021321833 @default.
• W3089405003 cites W3087059482 @default.
• W3089405003 cites W3090200844 @default.
• W3089405003 cites W4292528167 @default.
• W3089405003 doi "https://doi.org/10.1016/s2352-3018(20)30238-1" @default.
• W3089405003 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/33010241" @default.
• W3089405003 hasPublicationYear "2020" @default.
• W3089405003 type Work @default.
• W3089405003 sameAs 3089405003 @default.

• next